BMRN vs. SRPT, MYOK, TEVA, RETA, MRTX, BIIB, ALNY, NBIX, INCY, and UTHR
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Sarepta Therapeutics (SRPT), MyoKardia (MYOK), Teva Pharmaceutical Industries (TEVA), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Sarepta Therapeutics (NASDAQ:SRPT) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Sarepta Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.
Sarepta Therapeutics presently has a consensus price target of $164.00, suggesting a potential upside of 26.29%. BioMarin Pharmaceutical has a consensus price target of $106.11, suggesting a potential upside of 41.34%. Given Sarepta Therapeutics' higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Sarepta Therapeutics.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BioMarin Pharmaceutical has a net margin of 8.31% compared to BioMarin Pharmaceutical's net margin of 1.20%. Sarepta Therapeutics' return on equity of 5.34% beat BioMarin Pharmaceutical's return on equity.
BioMarin Pharmaceutical received 107 more outperform votes than Sarepta Therapeutics when rated by MarketBeat users. However, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 74.70% of users gave BioMarin Pharmaceutical an outperform vote.
In the previous week, Sarepta Therapeutics had 6 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 19 mentions for Sarepta Therapeutics and 13 mentions for BioMarin Pharmaceutical. Sarepta Therapeutics' average media sentiment score of 0.99 beat BioMarin Pharmaceutical's score of 0.64 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.
BioMarin Pharmaceutical has higher revenue and earnings than Sarepta Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical beats Sarepta Therapeutics on 10 of the 17 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
